as 07-26-2024 4:00pm EST
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | NOVATO |
Market Cap: | 16.3B | IPO Year: | 1999 |
Target Price: | $101.56 | AVG Volume (30 days): | 1.4M |
Analyst Decision: | Buy | Number of Analysts: | 19 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 1.06 | EPS Growth: | 178.95 |
52 Week Low/High: | $73.68 - $99.56 | Next Earning Date: | 08-05-2024 |
Revenue: | $2,471,644,000 | Revenue Growth: | 13.74% |
Revenue Growth (this year): | 15.66% | Revenue Growth (next year): | 12.76% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Mueller Brian | BMRN | EVP, Chief Financial Officer | May 30 '24 | Sell | $75.19 | 5,000 | $375,950.00 | 72,159 | SEC Form 4 |
Davis George Eric | BMRN | EVP, Chief Legal Officer | May 28 '24 | Sell | $75.29 | 2,779 | $209,225.35 | 56,157 | SEC Form 4 |
Davis George Eric | BMRN | EVP, Chief Legal Officer | May 28 '24 | Sell | $74.46 | 38,071 | $2,834,576.31 | 58,936 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | May 9 '24 | Sell | $81.62 | 20,000 | $1,632,400.00 | 474,994 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | May 9 '24 | Sell | $81.14 | 20,000 | $1,622,800.00 | 474,994 | SEC Form 4 |
Davis George Eric | BMRN | EVP, Chief Legal Officer | May 2 '24 | Sell | $85.01 | 1,850 | $157,268.50 | 56,157 | SEC Form 4 |
Ajer Jeffrey Robert | BMRN | EVP, Chief Commercial Officer | May 2 '24 | Sell | $82.91 | 5,000 | $414,550.00 | 66,767 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Apr 11 '24 | Sell | $90.99 | 20,000 | $1,819,800.00 | 474,994 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Apr 11 '24 | Sell | $91.26 | 20,000 | $1,825,200.00 | 474,994 | SEC Form 4 |
Burkhart Erin | BMRN | GVP, Chief Accounting Officer | Apr 10 '24 | Sell | $90.00 | 2,286 | $205,740.00 | 16,156 | SEC Form 4 |
Davis George Eric | BMRN | EVP, Chief Legal Officer | Mar 28 '24 | Sell | $88.34 | 24,602 | $2,173,340.68 | 55,856 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Mar 5 '24 | Sell | $85.51 | 1,000 | $85,510.00 | 561,203 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Mar 5 '24 | Sell | $86.71 | 1,000 | $86,713.00 | 560,203 | SEC Form 4 |
Ajer Jeffrey Robert | BMRN | EVP, Chief Commercial Officer | Mar 5 '24 | Sell | $87.07 | 4,000 | $348,280.00 | 94,047 | SEC Form 4 |
FUCHS HENRY J | BMRN | President, Worldwide R&D | Mar 5 '24 | Sell | $85.18 | 35,341 | $3,010,395.86 | 212,117 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Jan 18 '24 | Sell | $89.77 | 15,000 | $1,346,550.00 | 419,602 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Jan 18 '24 | Sell | $88.28 | 15,000 | $1,324,200.00 | 419,602 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Jan 8 '24 | Sell | $98.19 | 10,000 | $981,900.00 | 425,162 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Jan 8 '24 | Sell | $96.38 | 10,000 | $963,800.00 | 425,162 | SEC Form 4 |
BIENAIME JEAN JACQUES | BMRN | Director | Dec 21 '23 | Sell | $93.99 | 10,000 | $939,900.00 | 425,112 | SEC Form 4 |
Davis George Eric | BMRN | EVP, Chief Legal Officer | Dec 13 '23 | Sell | $95.30 | 13,764 | $1,311,709.20 | 55,710 | SEC Form 4 |
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Pharmaceutical Technology
2 days ago
MT Newswires
2 days ago
PR Newswire
2 days ago
Zacks
2 days ago
Argus Research
3 days ago
Zacks
3 days ago
PR Newswire
4 days ago
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.